FDA Approved: BREO ELLIPTA — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approved a supplemental application for BREO ELLIPTA submitted by GlaxoSmithKline LLC to update its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BREO ELLIPTA (fluticasone furoate and vilanterol trifenatate)

Snippet

SUPPL AP for BREO ELLIPTA (FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE)